Anlotinib Hydrochloride Capsule

DRUG15 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., The First Affiliated Hospital with Nanjing Medical University, Institute of Hematology & Blood Diseases Hospital, China, Ji Yongling

Conditions

Advanced Endometrial CancerAdvanced Gastric and Gastro-oesophageal Junction AdenocarcinomaAdvanced Non-squamous Cell Non-small Cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaCarcinomaDigestive System DiseasesGastric CancerGastroesophageal-junction Cancer

Phase 1

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

TerminatedNCT05193604

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Pancreatic Carcinoma

Start: 2022-03-24End: 2023-11-27Updated: 2023-12-08

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recurrent / Metastatic Nasopharyngeal Cancer

Start: 2022-01-31End: 2023-08-31Target: 90Updated: 2022-01-21

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma

Start: 2022-09-30End: 2024-07-31Target: 32Updated: 2022-09-22

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Liver Dysfunction

Start: 2022-10-31End: 2023-07-31Target: 30Updated: 2022-09-29

Phase 2

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Unresectable Metastatic Colorectal Cancer

Start: 2021-10-08End: 2024-06-30Target: 120Updated: 2021-10-20

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

TerminatedNCT05481645

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Endometrial Cancer, Sarcoma of Uterus

Start: 2022-08-26End: 2025-11-30Updated: 2026-01-09

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

RecruitingNCT05494060

The First Affiliated Hospital with Nanjing Medical UniversityCarcinoma, Digestive System Diseases, Gastric Cancer +4

Start: 2022-03-16End: 2027-02-28Target: 80Updated: 2023-11-07

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

RecruitingNCT06379087

Ji YonglingNon-Small Cell Lung Cancer

Start: 2024-05-01End: 2026-12-31Target: 20Updated: 2025-07-10

Phase 3

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Start: 2020-05-20End: 2023-12-31Target: 528Updated: 2020-05-13

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Non-squamous Cell Non-small Cell Lung Cancer

Start: 2019-08-08End: 2021-12-31Target: 369Updated: 2020-06-19

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruitingNCT04854668

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Metastatic Colorectal Cancer

Start: 2021-05-27End: 2026-12-01Updated: 2026-01-30

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Soft Tissue Sarcoma

Start: 2022-03-31End: 2024-06-30Target: 256Updated: 2022-02-18

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Squamous Non-Small Cell Lung Carcinoma

Start: 2023-02-28End: 2025-10-31Target: 570Updated: 2023-02-14

Phase 4

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

RecruitingNCT05830500

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Medullary Thyroid Cancer

Start: 2023-06-19End: 2028-12-31Target: 360Updated: 2023-07-25

Unknown Phase

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

RecruitingNCT05994365

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Thyroid Neoplasms

Start: 2023-08-31End: 2028-12-31Target: 380Updated: 2023-08-16

Related Papers

Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial).

Journal of Clinical Oncology2025-06-04

Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).

Journal of Clinical Oncology2025-05-282 citations

Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.

Journal of Clinical Oncology2025-05-282 citations

Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.

Journal of Clinical Oncology2025-05-28

Neoadjuvant hypofractionated radiotherapy plus tislelizumab with anlotinib followed by adjuvant tislelizumab with anlotinib in patients with resectable non-small cell lung cancer (NSCLC): Preliminary analysis of a phase II trial (NEO-PIONEER).

Journal of Clinical Oncology2025-05-28

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study)

Frontiers in Immunology2023-10-316 citations

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

Frontiers in Oncology2023-09-012 citations

Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as adjuvant therapy in ctDNA-positive gastric and esophagogastric junction adenocarcinoma: A protocol for a randomized, controlled, multicenter phase II clinical trial—EXPLORING study.

Journal of Clinical Oncology2023-01-24

Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.

2022-07-0115 citations

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

BMC Medicine2022-05-0620 citations